Covid-19 and weak da­ta force pipeline re­vamp at Rea­ta, but the best tri­als go for­ward — with some cre­ative adap­tions

A con­flu­ence of weak clin­i­cal re­sults and the ris­ing tide of prob­lems be­set­ting clin­i­cal tri­als in the age of coro­n­avirus has scut­tled a sig­nif­i­cant part of the pipeline ef­fort at Rea­ta Phar­ma­ceu­ti­cals.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER